Integrated Systems-genetic Analyses Reveal a Network Target for Delaying Glioma Progression

Overview

Journal Ann Clin Transl Neurol

Specialty Neurology

Date 2019 Aug 18

PMID 31420939

Citations 5

Authors

Liisi Laaniste

Prashant K Srivastava

Julianna Stylianou

Nelofer Syed

Silvia Cases-Cunillera

Kirill Shkura

Qingyu Zeng

Owen J L Rackham

Sarah R Langley

Andree Delahaye-Duriez

Kevin ONeill

Matthew Williams

Albert Becker

Federico Roncaroli

Enrico Petretto

Michael R Johnson

Affiliations

Soon will be listed here.

Abstract

Objective: To identify a convergent, multitarget proliferation characteristic for astrocytoma transformation that could be targeted for therapy discovery.

Methods: Using an integrated functional genomics approach, we prioritized networks associated with astrocytoma progression using the following criteria: differential co-expression between grade II and grade III IDH1-mutated and 1p/19q euploid astrocytomas, preferential enrichment for genetic risk to cancer, association with patient survival and sample-level genomic features. Drugs targeting the identified multitarget network characteristic for astrocytoma transformation were computationally predicted using drug transcriptional perturbation data and validated using primary human astrocytoma cells.

Results: A single network, M2, consisting of 177 genes, was associated with glioma progression on the basis of the above criteria. Functionally, M2 encoded physically interacting proteins regulating cell cycle processes and analysis of genome-wide gene-regulatory interactions using mutual information and DNA-protein interactions revealed the known regulators of cell cycle processes FoxM1, B-Myb, and E2F2 as key regulators of M2. These results suggest functional disruption of M2 via gene mutation or altered expression as a convergent pathway regulating astrocytoma transformation. By considering M2 as a multitarget drug target regulating astrocytoma transformation, we identified several drugs that are predicted to restore M2 expression in anaplastic astrocytoma toward its low-grade profile and of these, we validated the known antiproliferative drug resveratrol as down-regulating multiple nodes of M2 including at nanomolar concentrations achievable in human cerebrospinal fluid by oral dosing.

Interpretation: Our results identify M2 as a multitarget network characteristic for astrocytoma progression and encourage M2-based drug screening to identify new compounds for preventing glioma transformation.

Citing Articles

Identification of gene regulatory networks affected across drug-resistant epilepsies.

Francois L, Romagnolo A, Luinenburg M, Anink J, Godard P, Rajman M Nat Commun. 2024; 15(1):2180.

PMID: 38467626 PMC: 10928184. DOI: 10.1038/s41467-024-46592-2.

Involvement of Resveratrol against Brain Cancer: A Combination Strategy with a Pharmaceutical Approach.

Karthika C, Najda A, Klepacka J, Zehravi M, Akter R, Akhtar M Molecules. 2022; 27(14).

PMID: 35889532 PMC: 9320031. DOI: 10.3390/molecules27144663.

Differential Co-Expression Analyses Allow the Identification of Critical Signalling Pathways Altered during Tumour Transformation and Progression.

Savino A, Provero P, Poli V Int J Mol Sci. 2020; 21(24).

PMID: 33322692 PMC: 7764314. DOI: 10.3390/ijms21249461.

Systematic analysis to identify transcriptome-wide dysregulation of Alzheimer's disease in genes and isoforms.

Fan C, Chen K, Zhou J, Wong P, He D, Huang Y Hum Genet. 2020; 140(4):609-623.

PMID: 33140241 DOI: 10.1007/s00439-020-02230-7.

The Plant-Derived Compound Resveratrol in Brain Cancer: A Review.

Kiskova T, Kubatka P, Busselberg D, Kassayova M Biomolecules. 2020; 10(1).

PMID: 31963897 PMC: 7023272. DOI: 10.3390/biom10010161.

References

Yan J, Enge M, Whitington T, Dave K, Liu J, Sur I . Transcription factor binding in human cells occurs in dense clusters formed around cohesin anchor sites. Cell. 2013; 154(4):801-13. DOI: 10.1016/j.cell.2013.07.034. View

Malkki H . Trial Watch: Glioblastoma vaccine therapy disappointment in Phase III trial. Nat Rev Neurol. 2016; 12(4):190. DOI: 10.1038/nrneurol.2016.38. View

Basso K, Margolin A, Stolovitzky G, Klein U, Dalla-Favera R, Califano A . Reverse engineering of regulatory networks in human B cells. Nat Genet. 2005; 37(4):382-90. DOI: 10.1038/ng1532. View

Willsey A, Morris M, Wang S, Willsey H, Sun N, Teerikorpi N . The Psychiatric Cell Map Initiative: A Convergent Systems Biological Approach to Illuminating Key Molecular Pathways in Neuropsychiatric Disorders. Cell. 2018; 174(3):505-520. PMC: 6247911. DOI: 10.1016/j.cell.2018.06.016. View

Anders S, Pyl P, Huber W . HTSeq--a Python framework to work with high-throughput sequencing data. Bioinformatics. 2014; 31(2):166-9. PMC: 4287950. DOI: 10.1093/bioinformatics/btu638. View

Sahm F, Capper D, Jeibmann A, Habel A, Paulus W, Troost D . Addressing diffuse glioma as a systemic brain disease with single-cell analysis. Arch Neurol. 2011; 69(4):523-6. DOI: 10.1001/archneurol.2011.2910. View

Houillier C, Mokhtari K, Carpentier C, Criniere E, Marie Y, Rousseau A . Chromosome 9p and 10q losses predict unfavorable outcome in low-grade gliomas. Neuro Oncol. 2010; 12(1):2-6. PMC: 2940555. DOI: 10.1093/neuonc/nop002. View

Leek J, Johnson W, Parker H, Jaffe A, Storey J . The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics. 2012; 28(6):882-3. PMC: 3307112. DOI: 10.1093/bioinformatics/bts034. View

Li S, Labaj P, Zumbo P, Sykacek P, Shi W, Shi L . Detecting and correcting systematic variation in large-scale RNA sequencing data. Nat Biotechnol. 2014; 32(9):888-95. PMC: 4160374. DOI: 10.1038/nbt.3000. View

10.

Seguin L, Liot C, Mzali R, Harada R, Siret A, Nepveu A . CUX1 and E2F1 regulate coordinated expression of the mitotic complex genes Ect2, MgcRacGAP, and MKLP1 in S phase. Mol Cell Biol. 2008; 29(2):570-81. PMC: 2612504. DOI: 10.1128/MCB.01275-08. View

11.

Chen X, Muller G, Quaas M, Fischer M, Han N, Stutchbury B . The forkhead transcription factor FOXM1 controls cell cycle-dependent gene expression through an atypical chromatin binding mechanism. Mol Cell Biol. 2012; 33(2):227-36. PMC: 3554121. DOI: 10.1128/MCB.00881-12. View

12.

Lin H, Tang H, Keating T, Wu Y, Shih A, Hammond D . Resveratrol is pro-apoptotic and thyroid hormone is anti-apoptotic in glioma cells: both actions are integrin and ERK mediated. Carcinogenesis. 2007; 29(1):62-9. DOI: 10.1093/carcin/bgm239. View

13.

Staedtke V, Bai R, Laterra J . Investigational new drugs for brain cancer. Expert Opin Investig Drugs. 2016; 25(8):937-56. PMC: 5674816. DOI: 10.1080/13543784.2016.1182497. View

14.

Futreal P, Coin L, Marshall M, Down T, Hubbard T, Wooster R . A census of human cancer genes. Nat Rev Cancer. 2004; 4(3):177-83. PMC: 2665285. DOI: 10.1038/nrc1299. View

15.

Grossman R, Heath A, Ferretti V, Varmus H, Lowy D, Kibbe W . Toward a Shared Vision for Cancer Genomic Data. N Engl J Med. 2016; 375(12):1109-12. PMC: 6309165. DOI: 10.1056/NEJMp1607591. View

16.

Lu C, Xie M, Wendl M, Wang J, McLellan M, Leiserson M . Patterns and functional implications of rare germline variants across 12 cancer types. Nat Commun. 2015; 6:10086. PMC: 4703835. DOI: 10.1038/ncomms10086. View

17.

Buckner J, Shaw E, Pugh S, Chakravarti A, Gilbert M, Barger G . Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. N Engl J Med. 2016; 374(14):1344-55. PMC: 5170873. DOI: 10.1056/NEJMoa1500925. View

18.

Dehais C, Laigle-Donadey F, Marie Y, Kujas M, Lejeune J, Benouaich-Amiel A . Prognostic stratification of patients with anaplastic gliomas according to genetic profile. Cancer. 2006; 107(8):1891-7. DOI: 10.1002/cncr.22211. View

19.

Wang G, Guo X, Chen H, Lin T, Xu Y, Chen Q . A resveratrol analog, phoyunbene B, induces G2/M cell cycle arrest and apoptosis in HepG2 liver cancer cells. Bioorg Med Chem Lett. 2012; 22(5):2114-8. DOI: 10.1016/j.bmcl.2011.12.095. View

20.

Oshlack A, Wakefield M . Transcript length bias in RNA-seq data confounds systems biology. Biol Direct. 2009; 4:14. PMC: 2678084. DOI: 10.1186/1745-6150-4-14. View